Amgen (AMGN) reported $36.8B in revenue for fiscal 2025, +10.0% year on year. That ranks #151 by revenue among 2853 SEC filers and #22 in Healthcare. Net income was $7.7B, a net margin of 21.0%. Revenue has grown 6.3% a year on average since 2011 ($15.6B then). The fiscal 2025 balance sheet shows $90.6B in total assets, $9.1B in cash and $50.0B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $36.8B | +10.0% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $9.1B | +25.1% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $7.7B | +88.5% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $10.0B | −13.3% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.9B | +69.5% | FY20252025-12-31 |
| Total assetsAssets | $90.6B | −1.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $8.7B | +47.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $9.1B | −23.8% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $50.0B | −11.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $8.6B | $1.8B | Open → |
| Q2 20262026-06-30 | $10.1B | $2.4B | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 23 of 161 companies compared | 21.0% | |
| Operating marginRank 24 of 160 companies compared | 24.7% | |
| R&D as share of revenueRank 25 of 102 companies compared | 19.8% | |
| Cash as share of revenueRank 38 of 160 companies compared | 24.8% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Amgen Inc
- Ticker
- AMGN
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0000318154
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 1, 2026Open filing →
- 10-KFeb 13, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Molina HealthcareMOH | $45.4B | $472M |
| Abbott LaboratoriesABT | $44.3B | $6.5B |
| GSKGSK | $43.1B | $7.5B |
| AmgenAMGN | $36.8B | $7.7B |
| MedtronicMDT | $36.4B | $4.8B |
| Gilead SciencesGILD | $29.4B | $8.5B |
| MedlineMDLN | $28.4B | $1.2B |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Amgen — Key figures |url=https://companiesranked.com/en/company/amgen |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Amgen — Key figures. CompaniesRanked. https://companiesranked.com/en/company/amgenBibTeX
@misc{companiesranked-en-company-amgen-2026,
author = {{CompaniesRanked}},
title = {{Amgen — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/amgen}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000318154-26-000010 · February 13, 2026
{{cite web |title=Amgen — Key figures — 10-K (0000318154-26-000010) |url=https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-13}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.